arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Definium Therapeutics, Inc.

DFTX

$46.09 ▲ +1.66 (+3.75%) at close

8 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Definium Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Materials sector before making investment decisions.

Market Cap $4.1B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -44.6% ↘

FCF / Share $-1.47 ↘

Trailing P/E —

Price / Book 13.7x

FCF Yield —

Debt / Equity 0.12

info Valuation on last close. End-of-day price, Aug 6, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-183.79M

↓ -69.1% —

FCF / Share Free cash flow per share

$-1.47

↓ -31.1% —

Long-Term Debt Long-term obligations

$40.58M

↑ +85.7% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
EPS Growth YoY (%)	-33.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	36.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-32.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	45.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-69.1% Weak ↓ Weak Declining Year-over-year change in net income	-13.5% Weak ↑ Weak Improving Year-over-year change in net income	-68.6% Weak → Weak Stable Year-over-year change in net income	39.0% Excellent Excellent Year-over-year change in net income	-174.1% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	-31.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	31.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1.2% Weak Weak Year-over-year change in free cash flow	2.9% Caution Caution Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Return on Invested Capital (%)	-44.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-31.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-80.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-61.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-34.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-37.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-75.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-57.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-40.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-55.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-561%)	-45.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-122.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1121%)	-37.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-414%)	-61.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-611%)	-44.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-473%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Debt to Equity (x)	0.12x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-76%)	0.09x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-82%)	0.18x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-64%)	—	—	—	—	—
Interest Coverage (x)	-30.34x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-45.52x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-134.09x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-261.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	-201.40x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-217.26M	$-251.89M	$-85.58M	$-142.14M	$-133.54M	$-80.09M	—	—
Debt / EBITDA (x)	-0.24x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.21x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.15x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-2.06	$-1.54	$-2.44	$-1.84	$-3.40	—	—	—
Free Cash Flow per Share (USD)	$-1.47	$-1.12	$-1.64	$-1.62	$-1.67	—	—	—
Book Value per Share (USD)	$3.36	$3.21	$1.90	$3.97	$5.39	—	—	—
Tangible Book Value per Share (USD)	$3.16	$2.95	$1.42	$3.45	$4.68	—	—	—
Basic Weighted Avg Shares (shares)	89.33M	70.46M	39.16M	30.86M	27.38M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Working Capital (USD)	$352.62M	$242.77M	$71.63M	$128.16M	$126.81M	$78.51M	—	—
LT Debt (USD)	$40.58M	$21.85M	$14.13M	—	—	—	—	—
Total Equity (USD)	$332.33M	$241.45M	$78.13M	$150.92M	$151.66M	$75.87M	$4.78M	$0.00

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 May 29, 2019 10-K ↗
Net Income, GAAP (USD)	$-183.79M	$-108.68M	$-95.73M	$-56.80M	$-93.04M	$-33.94M	—	—
Operating Cash Flow (USD)	$-131.56M	$-79.13M	$-64.36M	$-50.14M	$-45.82M	$-23.60M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 24 quarters

Definium Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DFTX with peers